Principal investigator/program director (last, first, middle):

Principal Investigator/Program Director (Last, First, Middle): BIOGRAPHICAL SKETCH
Associate Professor of Internal Medicine EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include PROFESSIONAL EXPERIENCE:
1986-1989:
Resident in Internal Medicine, Emory Affiliated Hospitals, Atlanta, Georgia Fellow in Gastroenterology, University of Michigan, Ann Arbor, Michigan Senior Associate in Internal Medicine, Juha Kokko, Professor and Chairman of Medicine, Emory University School of Medicine, Atlanta, Georgia Lecturer in Internal Medicine, University of Michigan, Ann Arbor, MI Assistant Professor, Department of Internal Medicine, University of Michigan, Ann Arbor, MI Associate Professor, Department of Internal Medicine, University of Michigan, Ann Arbor, MI Professor, Department of Internal Medicine, University of Michigan, Ann Arbor, MI HONORS:
1978-1981
Alpha Epsilon Delta Pre-Medical Honor Society Glaxo Institute for Digestive Health Award for Clinical Research Award for a top ten abstract submitted to the Department of Internal Medicine's Research Day, University of Michigan Medical Center for "Hyperglycemia blunts the perception of electrical rectal stimulation by effects on central processing of afferent input." Presidential Poster selection, World Congress of Gastroenterology, Vienna, Austria for “Validation of the 13C-urea blood test for H. pylori infection: A US, multicenter trial” Astra Merck Fellow Research Award from the American College of Gastroenterology for “Interim analysis of a randomized, controlled trial to assess technical and clnical outcomes of a novel colorectal cancer screening strategy” (project mentor) 2001, 2003, 2005, 2007 Elected to “Best Doctors”. Best Doctors, Inc, Aiken, SC 2002 Honored as one of the “Best Doctors in Detroit”, Hour Detroit Magazine, September Selected to the Rome III Committee on Functional GI Disorders –Design of Treatment Trials Award for “Excellence in Teaching” from 2003 University of Michigan GI fellowship class Michigan Chapter American College of Physicians – “Governor’s Award” for service to the MI Rewarded for teaching excellence – Department of Internal Medicine, University of Michigan Internal Medicine Residency Program Award for “Excellence in Mentorship” from 2005 University of Michigan GI fellowship class Named as one of “America’s Top Physicians”
SELECTED PEER REVIEWED PUBLICATIONS:
1.
Chey WD, Carpenter S, Spybrook M, Nostrant T, Elta G, Scheiman J. Prolonged effect of omeprazole on the 14C-
urea breath test. Am J Gastroenterol 91:89-92, 1996.
Scheiman JM, Chey WD, Behler EM, Crause I, Elta GH. One week therapy for H. pylori: A randomized trial of
two treatment regimens. J Clin Gastroenterol 23:170-3, 1996.
Chey WD, Fey D, Woods M, Scheiman J, DelValle J, Nostrant T. Lansoprazole and ranitidine effect the accuracy
of the 14C-urea breath test by a pH dependent mechanism. Am J Gastroenterol 92:446-50, 1997.
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, First, Middle): Chey WD, Fisher L, Elta GH, Barnett J, Nostrant T, DelValle J, Scheiman J. Bismuth subsalicylate instead of
metronidazole with lansoprazole and clarithromycin for H. pylori infection: a randomized trial. Am J Gastroenterol.
92:1483-6, 1997.
Chey WD, Murthy U, Linscheer W, Barish C, Riff R, Rubin H, Safdi M, Schwartz H, Shah H, Wruble L, El-
Zamaity, HMT. The ChemTrak Hp ChekTM fingerstick, whole blood serology test for the detection of H. pylori
infection. Am J Gastroenterol 93:16-19, 1998.
Chey WD, Fisher L, Barnett J, Delvalle J, Elta GH, Nostrant T, Palaniappan J, Scheiman J. Triple therapy with low
versus high dose azithromycin to treat H. pylori infection. Aliment Pharmacol Ther 12:1263-7, 1998.
Fendrick AM, Chey WD, Fennerty MB. Estimating the demand for H. pylori confirmatory testing after eradication
treatment. Am J Med 107:133-6,1999.
Chey WD, Murthy U, Shaw S, Zawadski A, Linscheer W, Laine L. A comparison of 3 fingerstick, whole blood
antibody tests for H. pylori infection: a US multi-center trial. Am J Gastroenterol 94:1512-5, 1999.
Chey WD, Murthy U, Toskes P, Carpenter S, Laine L. The 13C-urea blood test accurately detects active H. pylori
infection: a US, multicenter trial. Am J Gastroenterol 94:1522-4, 1999.
10. Mao HV, Lak BV, Long T, Chung NQ, Thang DM, Hop TV, Chien NN, Hoan PQ, Henley KS, Connor BA, Stone CD, Chey WD. Omeprazole or ranitidine bismuth citrate with clarithromycin and amoxicillin for 10 days to treat H.
pylori infection: A randomized, controlled trial in Vietnamese patients with duodenal ulcer. Aliment Pharmacol
Ther 14:97-101, 2000.
11. Chey WD, Metz DC, Shaw S, Kearney D, Montague J, Murthy U. Appropriate timing of the 14C-Urea breath test to
establish eradication of H. pylori infection. Am J Gastroenterol 95:1171-4, 2000. 12. Stern MA, Fendrick AM, McDonnell WM, Gunaratnam N, Moseley RH, Chey WD. A randomized, controlled trial
to assess a novel colorectal cancer screening strategy: the conversion strategy. Am J Gastroenterol 95:2074-9, 2000. 13. Ladabaum U, Minoshima S, Hasler WL, Cross D, Chey WD, Owyang C. Localization of human cortical and
subcortical responses to gastric distention using positron emission tomography. Gastroenterology 120:369-76, 2001. 14. Chey WD, Shapiro B, Zawadski A, Goodman K. Gastric emptying characteristics of a novel 13C-octanoate-labelled
muffin meal. J Clin Gastroenterol 32:394-99, 2001. 15. Chey WD, Chathadi K, Montague J, Ahmed F, Murthy U. Intragastric acidification reduces the occurrence of false
negative urea breath test results in patients taking a proton pump inhibitor. Am J Gastroenterol 96:1028-32, 2001. 16. Chey WD, Fendrick M. Non-invasive H. pylori testing for the test and treat strategy: a decision analysis to assess the
impact of past infection on test choice. Arch Intern Med 161:2129-32, 2001. 17. Gonlachanvit S, Chey WD, Goodman KJ, Parkman HP. Effect of meal size and test duration on gastric emptying
and gastric myoelectrical activity as determined with simultaneous EGG and 13C-octanoate breath test in normal subjects using a muffin meal. Dig Dis Sci 46:2643-50, 2001. 18. Bjornsson E, Hasler WL Chey WD, Hooper F, Woods M, Owyang C. Impaired gastrocolonic response and
peristaltic reflex in idiopathic constipation: role of 5-HT3 pathways. Am J Physiol 275:G498-505, 1998. 19. Ladabaum U, Chey WD, Scheiman J, Fendrick M. Empiric therapy may be cost-effective compared to H. pylori
testing and treatment in some populations with uninvestigated dyspepsia. Aliment Pharacol Ther 16:1491-1501, 2002. 20. Chey WD, Olden K, Carter E, Boyle J, Drossman D, Chang L. Utility of the Rome I and Rome II criteria for IBS in
US women. Am J Gastroeterol 97:2803-11, 2002. 21. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic
review. Am J Gastroenterol 97:2812-19, 2002. 22. Brown WH, Chey WD, Elta GH. Number of Responses on a Review of Systems Questionnaire Predicts the
Diagnosis of Functional GI Disorders. J Clin Gastroenterol 36:2222-27, 2003. 23. Chey WD, Huang B, Lukasik N, Jackson RL. Lansoprazole vs. Esomeprazole in symptomatic gastro-oesophageal
reflux disease: A double-blind, radomised, multicentre trial in 3000 patients confirms comparable symptom relief. Clin Drug Invest 23:69-84, 2003. 24. Schoenfeld P, Chey WD. An evidence based approach to clinical practice guidelines – diagnosis and treatment of
Irritable Bowel Syndrome. Clinical Gastroenterol Hepatol 1:322-7, 2003. 25. Cash BD, Chey WD. Irritable Bowel Syndrome: A systematic review. Family Medicine Clinics of North America
26. Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ. Long-term efficacy and safety of
Alosetron in women with severe diarrhea-predominant Irritable Bowel Syndrome. Am J Gastroenterol 99:2195-2203, 2004. Continuation Format Page
Principal Investigator/Program Director (Last, First, Middle): 27. Fischer R, Thistle J, Lembo A, Novick J, O’Kane P, Chey WD, Beglinger C, Rueegg P, Shi V, Dogra A, Luo D,
Earnest D. Tegserod does not alter fasting or meal-induced biliary tract motility. Am J Gastroenerol 99:1342-9, 2004. 28. Chey WD. Erosive esophagitis and NERD: Can we really classify patients with heartburn using endoscopic
findings? Clinical Gastroenterol Hepatol 2:654-5, 2004 29. Johanson JF, Wald A, Tougas G, Chey WD, Novick J, Lembo A, Fordham F, Guella M, Nault B. Tegaserod is
effective and well tolerated in patients with chronic constipation: Findings from a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol and Hepatol 2:796-805, 2004. 30. Saad R, Chey WD. A clinician’s guide to the diagnosis and treatment of H. pylori. Clev Clin J Med 72:109-126,
31. Gonlachanvit S, Rhee J, Sun WM, Chey WD. Effect of acute acoustic stress on anorectal function and sensation in
healthy humans. Neurogastroenterol Motil 17:222-8, 2005. 32. Chey WD, Inadomi, JM, Booher A, Sharma VK, Fendrick AM, Howden CW. Primary care physicians perceptions
and practices on the management of GERD: Results of a national survey, Am J Gastroenterol 100:1243-50; 2005. 33. Chey WD, Cash BD. Cilansetron: A new serotonergic agent for the irritable bowel syndrome and diarrhea. Expert
34. Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious
complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol, in press. 35. Dickman R, Green C, Chey WD, Jones MP, Eisen GM, Ramirez F, Briseno M, Garewal HS, Fass R. Clinical
predictors of Barrett’s esophagus length, in preparation. Gastrointestinal Endoscopy, in press. 36. Saad R, Schoenfeld P, Chey WD. Levofloxacin triple or PPI quadruple salvage therapy for persistent Helicobacter
pylori infection: Results of a meta-analysis. Am J Gastroenterol, in press. 37. Ahmet F, Chey WD, Murthy U. Evaluation of the Ez-HBT Helicobacter blood test to establish Helicobacter pylori
eradication, Aliment Pharm Ther, 22:875-80, 2005. 38. Dickman R, Green C, Chey WD, Jones MP, Eisen GM, Ramirez F, Briseno M, Garewal HS, Fass R. Clinical
predictors of Barrett’s esophagus length. Gastrointestinal Endoscopy, 62:675-81, 2005.
39. Saad R, Chey WD. What is the most effective treatment for patients with dyspepsia who are negative for
Helicobacter pylori infection? Nature Clinical Practice Gastroenterology & Hepatology, 3:20-21, 2006.
40. Chey WD, Eswaren S, Howden CW, Inadomi J, Fendrick AM, Scheiman J. Primary care physicians perceptions of
NSAID and aspirin-associated toxicity: Results of a national survey. Aliment Pharm Ther, 23:655-68, 2006.
41. Saad R, Chey WD. Tegaserod in the treatment of irritable bowel syndrome with constipation. Women’s Health, 2:
29-42, 2006.
42. Saad R, Schoenfeld P, Chey WD. Levofloxacin triple or PPI quadruple salvage therapy for persistent Helicobacter
pylori infection: Results of a meta-analysis. Am J Gastroenterol, 101:488-96, 2006. 40. Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious
complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol, 101:1-11; 2006. 41. Longstreth G, Thompson WG, Chey WD, Houghton L, Mearin F, Spiller R. RomeIII: Functional Bowel Disorders.
42. Irvine EJ, Whitehead W, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldehuyzen van Zanten S. Rome III: Design
of treatment trials. Gastroenterol, 130:1538-51, 2006. 43. Saad R, Chey WD. Current and emerging therapies for functional dyspepsia. Aliment Pharmacol Ther, 24;475-92,
44. Saad R, Chey WD. Treatment of H. pylori infection in 2006. Gastreonterol Hepatol Annual Review, 1:30-35, 2006.
Research Support
Ongoing Research Support
1. GCRC for “Pilot feasibility study of structure-function relationships in pediatric fecal incontinence”
Principal Investigator: Cheryl Gariepy, MD Co-investigators: WD Chey, B Felt, P Strouse Funding period: 11/01/05-4/30/07 ($26,108) 2. Salix for “A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 3 different doses of rifaximin bid for 2 or 4 weeks in the treatment of patients with IBS-D” Continuation Format Page
Principal Investigator/Program Director (Last, First, Middle): Principal Investigator: WD Chey, MD Co-investigators: R Saad, MD Funding period: 5/1/06-1/31/09 ($44,075) 3. Alizyme for “A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study of renzapride in women with constipation-predominant IBS” Principal Investigator: WD Chey, MD Co-investigators: R Saad, MD Funding period: 3/20/06-10/30/07 ($63,302) 4. Alizyme for “A phase III, multicenter, open label, extension study to evaluate the long-term safety of renzapride in women with constipation-predominant IBS” Principal Investigator: WD Chey, MD Co-investigators: R Saad, MD Funding period: 7/6/06-8/30/08 ($43,704) 5. Novartis for “The effects of tegaserod on orocecal transit in elderly patients with chronic constipation” Principal Investigator: WD Chey, MD Co-investigators: H Parkman, I Bottoli, D Joseph Funding period: 7/1/06-6/30/07 ($750,000 for 3 sites - $244,000 to UM) 6. Trine Pharmaceuticals for “A randomized, double-blind placebo controlled study to assess the safety and efficacy of TRN-002 for the symptomatic treatment of diarrhea-predominant IBS in females” Co-Investigators: R. Saad MD, D Brenner, MD Funding period: 10/16/06-10/31/07 ($33,064) 7. Prometheus Laboratories for “The value of diagnostic testing in Irritable Bowel Syndrome” Principal Investigator: WD Chey, MD Co-Investigators: B Cash Funding period 9/12/2003-12/30/2007 ($31,265) 8. Janssen Pharmaceuticals for “Nonerosive Reflux Disease: A study to understand etiology and predictors of response Co-investigators: M Cleary, M Shaw, J Inadomi Funding period: 2/1/02-4/30/07 ($80,579) 9. Janssen Pharmaceuticals for "Esophageal Sensation in Patients with Heartburn: Correlation of Esophageal Sensation Co-investigators: J Rubenstein, B Nojkov Funding period: 2/1/04-1/31/08 ($52,948) 10. TAP for “NSAID and aspirin utilization amongst US primary care physicians: A follow-up survey” Funding period: 4/27/06-4/26/07 ($18,649) Selected Completed Research Support
1. Novartis for “A randomized, double-blind, placebo controlled multi-center study to assess the efficacy, safety, and
tolerability of tegaserod 2 mg bid and 6 mg bid given orally vs. placebo in patients with chronic constipation” Principal Investigator: WD Chey, MD Co-Investigators: C Owyang, G Elta, J Barnett Funding period: 5/1/01-11/1/02 Project description: This industry initiated study attempts to evaluate the effect of tegaserod on clinical outcomes in patients with chronic constipation. 2. Forest Laboratories for “Safety and efficacy of dexloxiglumide in female patients with constipation-predominant irritable bowel syndrome” Principal Investigator: WD Chey, MD Co-Investigators: C Owyang, G Elta Funding period: 2/1/02-3/31/03 Continuation Format Page
Principal Investigator/Program Director (Last, First, Middle): Project description: This industry initiated study attempts to evaluate the effectiveness of a novel CCK antagonist in patients with constipation-predominant irritable bowel syndrome. 3. Vela Pharmaceuticals for “A double-blind randomized, placebo-controlled study of R-Tofisopam in outpatients with Irritable Bowel Syndrome” Principal Investigator: WD Chey, MD Co-Investigators: C Owyang, WL Hasler, J Wiley Funding period 9/9/2003-6/30/2004 ($50,133) 4. Phase I SBIR for “A novel diagnostic test for irritable bowel syndrome” Funding period: 3/1/03-2/28/05 ($27,394) 5. Novartis for “A 6 week randomized, double-blind, double-dummy placebo controlled, multicenter study to assess the effect of tegaserod 2mg TID on dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy” Principal Investigator: WD Chey, MD Co-investigators: C Owyang, WL Hasler, J Wiley, L Fisher Funding period: 2/25/04-6/30/2005 ($57,486) 6. Novartis Pharmaceuticals for "A 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group, clinical study to evaluate the efficacy of tegaserod in relieving the symptoms of female patients with IBS, excluding those with predominant diarrhea IBS" Principal Investigator: WD Chey, MD Co-investigators: C Owyang, WL Hasler, J Wiley, L Fisher Funding period: 1/11/04-7/31/05 ($30,517) 7. Trine Pharmaceuticals for “A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRN-002 for the symptomatic treatment of diarrhea-predominant irritable bowel syndrome” Principal Investigator: WD Chey, MD Co-investigators: C Owyang, WL Hasler, J Wiley, L Fisher Funding period: 12/1/04-11/30/2005 ($40,679) 8. Smart Pill Diagnostics for “Medical Utilization in patients with gastroparesis” Principal Investigator: WD Chey, MD Co-investigators: John Wo Funding period: 11/1/04-10/31/2005 ($25,389) 9. Smart Pill Diagnostics for “A comparison of ACT GI Monitoring system with scintigraphic gastric emptying procedure for determining gastric residence time” Principal Investigator: WD Chey, MD Co-investigators: Braden Kuo, Micheal Sitrin, Henry Parkman, Kenneth Koch Funding period: 2/1/05-8/31/2005 ($TBA) 10. Rome Foundation for Disorders of GI Function for “Validation of the Rome III modular questionnaire” Principal Investigator: WD Chey, MD Co-investigators: R Saad, MD Funding period: 10/1/05-4/31/2006 ($7,500) 11. Sucampo Pharmaceuticals for “A 12 week, multicenter, double-blind, randomized efficacy and safety study of lubiprostone for the treatment of constipation-predominant irritable bowel syndrome” Principal Investigator: WD Chey, MD Co-investigators: R Saad, MD Funding period: 10/1/05-12/31/2006 ($50,079) 12. Sucampo Pharmaceuticals for “An open-label study of lubiprostone for constipation-predominant irritable bowel syndrome” Co-investigators: R Saad, MD Funding period: 1/1/06-3/31/2007 ($52,614) Continuation Format Page

Source: http://www.myuofmhealth.com/mgpc/Peptide%20Center%20Web%20Info/Website%20Biosketches/Chey_William%20biosketch%20.pdf